Dr Reddy’s Growth Strategy Sets Sights On Six Spaces
Dr Reddy’s chief operating officer Erez Israeli says six key areas – the US, China, Russia, India, APIs and hospital drugs – underpin the Indian company’s growth ambitions, with small-molecule generics remaining the firm’s “bread and butter”.
You may also be interested in...
Dr Reddy’s is expanding its portfolio by acquiring 42 ANDAs in the US as it seeks to develop its North American and emerging market operations.
Dr Reddy’s has strengthened operational efficiency for its generics API customers by launching a customer service portal that enables users to “manage the whole business process in real time”.
Dr Reddy’s has been given the all-clear for its Indian formulations manufacturing facility in Duvvada, Visakhapatnam, after the FDA issued an EIR closing out an inspection at the plant that has suffered longstanding quality issues.